WO2003050097A1 - Sel de sodium d'un derive benzyl thiazolidine-2,4-dione et hydrate de sel de sodium - Google Patents
Sel de sodium d'un derive benzyl thiazolidine-2,4-dione et hydrate de sel de sodium Download PDFInfo
- Publication number
- WO2003050097A1 WO2003050097A1 PCT/JP2002/012891 JP0212891W WO03050097A1 WO 2003050097 A1 WO2003050097 A1 WO 2003050097A1 JP 0212891 W JP0212891 W JP 0212891W WO 03050097 A1 WO03050097 A1 WO 03050097A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sodium salt
- hydrate
- compound
- methyl
- vivo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention is effective for preventing and / or treating metabolic diseases such as diabetes and hyperlipidemia as peroxisome proliferator-activated receptor (PPAR) agonists, which are nuclear receptors, and particularly as human PPAR agonists.
- PPAR peroxisome proliferator-activated receptor
- the present invention relates to a sodium salt of a benzylthiazolidine-1,2,4-dione derivative, a hydrate of the salt and a method for producing the same.
- Compound (I) is used as a peroxisome proliferator-activated receptor (PPAR) agonist, which is a nuclear receptor, and particularly as a human PPAR agonist, for preventing and / or treating metabolic diseases such as diabetes and hyperlipidemia. It is known to be useful for medicinal use, and is disclosed in WO 01/14350 together with a production method thereof. However, the sodium salt of the compound (I) or a hydrate thereof, and their pharmacologically excellent properties are not specifically known, and
- the sodium salt of the compound (I) or a hydrate thereof can be prepared by an appropriate alcohol solvent and sodium hydroxide without purifying the crude crystals of the compound (I) obtained according to the production method described in WO 01/14350.
- an aqueous solution of Trim it can be obtained in a simple operation with good yield and high purity.
- the hydrate of the sodium salt of the compound (I) can be obtained by alkali treatment, washing the precipitated crystals with a small amount of isopropyl alcohol, and drying.
- the sodium salt of compound (I) containing no water can be obtained by treating with alkali, adding a large amount of isopropyl alcohol to precipitate the salt, stirring for a while, and drying.
- a sodium salt of compound (I) or a hydrate thereof It was found that when the substance was orally administered to animals, the blood concentration of compound (I) was increased and the absorbability was improved as compared with the case where compound (I), which is the free acid, was orally administered. Was. Thus, the use of the sodium salt of compound (I) or a hydrate thereof improves the absorbability upon oral administration, maintains an effective concentration in vivo, and has good pharmacokinetics as a pharmaceutical. It is expected to show.
- the sodium salt of the compound (I) or a hydrate thereof is useful as a derivative of the compound (I) having improved absorption.
- N-cyclohexylmethyl-5- (2,4-dioxothiazolidin-1-5-yl) methyl 2-methylmethoxybenzamide (coarse crystal) 20.0 g (53.1 mmol)
- an aqueous sodium hydroxide solution (2.19 g of sodium hydroxide / 22 mL of purified water) was added dropwise. 6 mL of purified water was added thereto to dissolve the mixture, and the mixture was stirred for 30 minutes, and then cooled to 10 ° C or less.
- HPLC conditions Column: Inertsil ODS-2 (4.6mraIDx250mm), Pre-column: Inertsil ODS-2 (4. OmmlDxlOmm)
- Administration method and dosage The following various administration methods (a, b) were administered: a) Oral administration of aqueous solution: Use a solution of the drug substance (400 mg) dissolved in distilled water (80 mL), and administer the dosage (10 mg / 2 mL / kg). Oral administration using sonde (No.15)
- Oral administration of forcepsel The drug substance (10 mg / kg) was orally administered in capsules (No. 000) of the Japanese Pharmacopoeia.
- Sampling About 0.1 mL of blood was collected from the cephalic vein at 0.17, 0.5, 1, 4, 8, and 24 hours after administration. The collected blood was centrifuged at 7200 G for 5 minutes to obtain serum. The obtained serum was stored at ⁇ 20 ° C. until measurement.
- Pretreatment 50 L of serum and 100 / L of acetonitril, collected after administration, were mixed in a laboratory lab tube and centrifuged at 7200 G for 5 minutes. 100 zL of the resulting supernatant was injected into the HPLC system.
- a calibration curve was prepared in the concentration range of 0.1 SO g / mL using the drug substance in the same lot as the administered drug substance. The limit of quantification was determined at 0.1 zg / mL.
- Analytical ram L column (4.6mm idx 150mm, 5 ⁇ 111, Chemical Substance Evaluation Research Organization)
- Pharmacokinetic analysis The following various pharmacokinetic parameters were determined from the obtained serum concentrations.
- the present invention has established an industrially advantageous production method for providing a sodium salt of the compound (I) or a hydrate thereof which is useful as a medicament, and has a high purity and a high quality.
- a sodium salt of the compound (I) or a hydrate thereof which is useful as a medicament, and has a high purity and a high quality.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003551122A JPWO2003050097A1 (ja) | 2001-12-11 | 2002-12-10 | ベンジルチアゾリジン−2,4−ジオン誘導体のナトリウム塩及びその水和物 |
AU2002349535A AU2002349535A1 (en) | 2001-12-11 | 2002-12-10 | Sodium salt of benzyl thiazolidine-2,4-dione derivative and hydrate thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-377076 | 2001-12-11 | ||
JP2001377076 | 2001-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003050097A1 true WO2003050097A1 (fr) | 2003-06-19 |
Family
ID=19185128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/012891 WO2003050097A1 (fr) | 2001-12-11 | 2002-12-10 | Sel de sodium d'un derive benzyl thiazolidine-2,4-dione et hydrate de sel de sodium |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2003050097A1 (ja) |
AU (1) | AU2002349535A1 (ja) |
WO (1) | WO2003050097A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001014350A1 (fr) * | 1999-08-23 | 2001-03-01 | Kyorin Pharmaceutical Co., Ltd. | Derives de benzylthiazolidine-2,4-dione substitues |
-
2002
- 2002-12-10 JP JP2003551122A patent/JPWO2003050097A1/ja active Pending
- 2002-12-10 AU AU2002349535A patent/AU2002349535A1/en not_active Abandoned
- 2002-12-10 WO PCT/JP2002/012891 patent/WO2003050097A1/ja active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001014350A1 (fr) * | 1999-08-23 | 2001-03-01 | Kyorin Pharmaceutical Co., Ltd. | Derives de benzylthiazolidine-2,4-dione substitues |
Also Published As
Publication number | Publication date |
---|---|
JPWO2003050097A1 (ja) | 2005-04-21 |
AU2002349535A1 (en) | 2003-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5670338B2 (ja) | ミトコンドリアの膜透過性遷移の阻害剤として有用なアクリルアミド誘導体 | |
US20150141659A1 (en) | Solid forms of an antiviral compound | |
TWI548630B (zh) | 1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸結晶型及其製造方法 | |
CN104803891B (zh) | 胰高血糖素拮抗剂 | |
JP2001521532A (ja) | 置換されたフエニル誘導体、その製造方法及びその使用方法 | |
JP6716023B2 (ja) | アンドロゲン受容体拮抗薬の結晶形及びその製造方法並びに用途 | |
JP2007145872A (ja) | ランソプラゾール安定化方法 | |
RU2719484C2 (ru) | Натриевая соль ингибитора транспортера мочевой кислоты и его кристаллическая форма | |
US20110269838A1 (en) | Novel processes and pure polymorphs | |
JPWO2002096875A1 (ja) | 鎮痛作用を有する4−ヒドロキシピペリジン誘導体 | |
CN107922375A (zh) | 靶向idh2突变的抗肿瘤化合物及其使用方法 | |
WO2006078037A1 (ja) | チアゾリジンジオン化合物の製造方法及びその製造中間体 | |
WO2003050097A1 (fr) | Sel de sodium d'un derive benzyl thiazolidine-2,4-dione et hydrate de sel de sodium | |
CZ20011417A3 (cs) | Sklovitá forma 8-(3-(N-((E)-3-(6-acetamidopyridin-3-yl)-akryloylglycyl)-N-methylamino)-2,6-dichlorbenzyloxy)-2-methylchinolinu | |
JPWO2008029912A1 (ja) | シクロオキシゲナーゼ1(cox−1)選択的阻害活性を有するベンズアミドを骨格とする化合物 | |
KR20230024976A (ko) | 인덴 화합물, 이의 약제학적 조성물, 및 이의 치료학적 적용 | |
WO2021233133A1 (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
WO2011163469A1 (en) | Hydrated form of anti-inflammatory roflumilast-n-oxide | |
US8754129B2 (en) | Crystalline vorinostat form VI | |
CN107235960B (zh) | 酰胺类衍生物、其制备方法及其在医药上的用途 | |
CN102086212A (zh) | 抗真菌剂-2,3,4,5-四氢-4H-苯并[b]噻喃并[4,3-c]吡唑-2-甲酰胺衍生物 | |
CN111556748A (zh) | 一种局部麻醉药物 | |
EP4257583A1 (en) | Biphenyl pyrrolidine and biphenyl dihydroimidazole derivatives for inhibiting activity of 5-ht7 serotonin receptor, and pharmaceutical composition comprising same as active ingredient | |
JPH0234941B2 (ja) | ||
WO2020156150A1 (zh) | 泊马度胺前体药物盐的多晶型物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003551122 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |